Long-term outcomes in AML patients in Sweden
Author Information
Author(s): Åström M, Bodin L, Nilsson I, Tidefelt U
Primary Institution: Örebro Medical Center Hospital
Hypothesis
What are the long-term outcomes and prognostic variables in unselected acute myeloid leukaemia (AML) patients?
Conclusion
The study found that the median survival for AML patients was 5.8 months, with a 5-year survival probability of 9.3%.
Supporting Evidence
- 56% of patients received high-dose induction treatment.
- The probability of survival at 5 years was 9.3%.
- Age, LDH, and kidney function were independent prognostic variables.
Takeaway
This study looked at a group of people with a type of blood cancer called AML and found that most didn't live very long after being diagnosed.
Methodology
The study reviewed hospital records and cancer registries for AML patients diagnosed between 1987 and 1992.
Limitations
The study may not represent all AML patients as it only includes those diagnosed in a specific region and time frame.
Participant Demographics
The median age of patients was 69.5 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website